Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cannapharmarx ( (CPMD) ) has issued an update.
CannaPharmaRX, Inc. has entered into letter agreements with payment schedules to address outstanding debts owed to two significant debtholders. This move aims to prevent additional defaults while retaining capital for operational growth. The company filed an 8-K to include the actual payment schedule agreements that were mistakenly omitted from the exhibits of their 10Q for the period ending June 30, 2025.
Spark’s Take on CPMD Stock
According to Spark, TipRanks’ AI Analyst, CPMD is a Underperform.
Cannapharmarx presents a high-risk investment due to severe financial instability, reflected in negative equity and cash flow issues. The absence of technical analysis indicators further adds uncertainty. Without any positive valuation metrics or corporate events to offset the risks, the stock score is significantly low.
To see Spark’s full report on CPMD stock, click here.
More about Cannapharmarx
Technical Sentiment Signal: Sell
Current Market Cap: $1.99M
Learn more about CPMD stock on TipRanks’ Stock Analysis page.